Successful treatment of refractory prurigo nodularis with abrocitinib

Key Clinical Message Prurigo nodularis is frequently difficult to manage with conventional therapy. Given the pathogenesis and refractory nature, we demonstrate a case in which inhibition of JAK–STAT signaling may significantly improve prurigo nodularis. Based on the results, we would like to draw a...

Full description

Saved in:
Bibliographic Details
Published inClinical case reports Vol. 12; no. 3; pp. e8606 - n/a
Main Authors Sun, Fang, Wu, Zhenzhen
Format Journal Article
LanguageEnglish
Published England John Wiley & Sons, Inc 01.03.2024
John Wiley and Sons Inc
Wiley
Subjects
abrocitinib
Case Report
Conflicts of interest
Consent
Cytokines
Dermatology
itching
JAK inhibitor
prurigo nodularis
Pruritus
JAK inhibitor
abrocitinib
itching
prurigo nodularis
Online AccessGet full text

Cover

More Information
Summary:Key Clinical Message Prurigo nodularis is frequently difficult to manage with conventional therapy. Given the pathogenesis and refractory nature, we demonstrate a case in which inhibition of JAK–STAT signaling may significantly improve prurigo nodularis. Based on the results, we would like to draw a conclusion that abrocitinib as an inhibitor of Jak is a promising choice for the treatment of prurigo nodularis.
ISSN:2050-0904
2050-0904
DOI:10.1002/ccr3.8606